Graft-Versus-Host Disease: A Surge of Developments

por Riddell, Stanley R, Appelbaum, Frederick R
Publicado 2007

The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant

por Sanders, Jean E., Hoffmeister, Paul A., Storer, Barry E., Appelbaum, Frederick R., Storb, Rainer F., Syrjala, Karen L.
Publicado 2009

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies

por Othus, Megan, Sekeres, Mikkael A., Nand, Sucha, Garcia-Manero, Guillermo, Appelbaum, Frederick R., Erba, Harry P., Estey, Eli
Publicado 2018

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

por Orvain, Corentin, Rodríguez-Arbolí, Eduardo, Othus, Megan, Sandmaier, Brenda M., Deeg, H. Joachim, Appelbaum, Frederick R., Walter, Roland B.
Publicado 2023

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

por Othus, Megan, Garcia-Manero, Guillermo, Godwin, John E., Weick, James K., Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H.
Publicado 2022

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

por Bar, Merav, Wood, Brent L., Radich, Jerald P., Doney, Kristine C., Woolfrey, Ann E., Delaney, Colleen, Appelbaum, Frederick R., Gooley, Ted A.
Publicado 2014

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

por Othus, Megan, Wood, Brent L., Stirewalt, Derek L., Estey, Elihu H., Petersdorf, Stephen H., Appelbaum, Frederick R., Erba, Harry P., Walter, Roland B.
Publicado 2016

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML

por Sorror, Mohamed L., Agarwal, Shirali, Othus, Megan, Lynch, Ylinne, Nyland, Jennifer E., Percival, Mary‐Elizabeth, Becker, Pamela S., Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2020

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute...

por Orvain, Corentin, Wilson, Jacob A., Fang, Min, Sandmaier, Brenda M., Rodríguez-Arbolí, Eduardo, Wood, Brent L., Othus, Megan, Appelbaum, Frederick R., Walter, Roland B.
Publicado 2022

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia

por Zhou, Yi, Othus, Megan, Araki, Daisuke, Wood, Brent L., Radich, Jerald P., Halpern, Anna B., Mielcarek, Marco, Estey, Elihu H., Appelbaum, Frederick R., Walter, Roland B.
Publicado 2016

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

por Zarling, Lucas C., Othus, Megan, Sandmaier, Brenda M., Milano, Filippo, Schoch, Gary, Davis, Chris, Bleakley, Marie, Deeg, H. Joachim, Appelbaum, Frederick R., Storb, Rainer, Walter, Roland B.
Publicado 2022

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation

por Castilla-Llorente, Cristina, Martin, Paul J., McDonald, George B., Storer, Barry E., Appelbaum, Frederick R., Deeg, H. Joachim, Mielcarek, Marco, Shulman, Howard, Storb, Rainer, Nash, Richard A.
Publicado 2014

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell tra...

por Rodríguez-Arbolí, Eduardo, Othus, Megan, Orvain, Corentin, Zarling, Lucas C., Sandmaier, Brenda M., Milano, Filippo, Schoch, Gary, Davis, Chris, Deeg, H. Joachim, Appelbaum, Frederick R., Storb, Rainer, Walter, Roland B.
Publicado 2022

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell...

por Walter, Roland B., Gyurkocza, Boglarka, Storer, Barry E., Godwin, Colin D., Pagel, John M., Buckley, Sarah A., Sorror, Mohamed L., Wood, Brent L., Storb, Rainer, Appelbaum, Frederick R., Sandmaier, Brenda M.
Publicado 2014

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML

por Morsink, Linde M., Othus, Megan, Bezerra, Evandro D., Wood, Brent L., Fang, Min, Sandmaier, Brenda M., Mielcarek, Marco, Schoch, Gary, Storb, Rainer, Joachim Deeg, H., Appelbaum, Frederick R., Walter, Roland B.
Publicado 2020

Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease

por Furlong, Terry, Martin, Paul, Flowers, Mary E.D., Carnevale-Schianca, Fabrizio, Yatscoff, Randy, Chauncey, Thomas, Appelbaum, Frederick R., Deeg, H. Joachim, Doney, Kris, Witherspoon, Robert, Storer, Barry, Sullivan, Keith M., Storb, Rainer, Nash, Richard A.
Publicado 2009

Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission

por Walter, Roland B., Pagel, John M., Gooley, Ted A., Petersdorf, Effie W., Sorror, Mohamed L., Woolfrey, Ann E., Hansen, John A., Salter, Alexander I., Lansverk, Emily, Stewart, F. Marc, O’Donnell, Paul V., Appelbaum, Frederick R.
Publicado 2010

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

por Walter, Roland B., Othus, Megan, Burnett, Alan K., Löwenberg, Bob, Kantarjian, Hagop M., Ossenkoppele, Gert J., Hills, Robert K., Ravandi, Farhad, Pabst, Thomas, Evans, Anna, Pierce, Sherry R., Vekemans, Marie-Christiane, Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2014

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

por Michelson, Andrew P., McDonough, Shannon, Willman, Cheryl L., Koegle, Eric R., Godwin, John E., Petersdorf, Stephen H., List, Alan F., Othus, Megan, Appelbaum, Frederick R., Radich, Jerald P., Ganapathi, Mahrukh K., Advani, Anjali S., Ganapathi, Ram N.
Publicado 2020

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

por Vo, Phuong, Gooley, Ted A., Rajendran, Joseph G., Fisher, Darrell R., Orozco, Johnnie J., Green, Damian J., Gopal, Ajay K., Haaf, Robyn, Nartea, Margaret, Storb, Rainer, Appelbaum, Frederick R., Press, Oliver W., Pagel, John M., Sandmaier, Brenda M.
Publicado 2020